Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).
Novel SERM Reduces Mammographic Breast Density in Premenopausal Population
Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.
Applying Updated Breast Cancer Findings From ASCO to Clinical Practice
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups
Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.
Finding a Place for Exercise Oncology in the Treatment of Breast Cancer
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Breast Cancer Breakthroughs: 2024 ESMO Highlights
Neil M. Iyengar, MD, highlighted the most important data in breast cancer to come from 2024 ESMO.
Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer
Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.